July 20, 2012
Bad Homburg v.d.H.
Conference Call and Live Webcast
Monday, July 23, 2012, 2.30 p.m. CEST
Fresenius Kabi has signed a definitive agreement to
acquire Fenwal Holdings, Inc., a leading U.S.-based provider
of transfusion technology products for blood collection,
separation and processing, from TPG and Maverick Capital.
The acquisition marks another major step in Fresenius
Kabi's growth strategy. The company had announced
previously that expanding its medical devices/transfusion
technology segment is a priority. Fresenius Kabi will now
become a global leader in transfusion technology.
In 2011, Fenwal had sales of US$614 million with an adjusted
EBITDA of US$90 million. The company, with about 4,900
employees worldwide, runs a state-of-the-art R&D center and
operates five manufacturing facilities.
Ulf Mark Schneider, CEO of Fresenius, said: "Acquiring
Fenwal is a unique opportunity to significantly expand
Fresenius Kabi's medical devices/transfusion technology
segment. In addition, Fresenius Kabi will benefit from a more
balanced product portfolio. Fenwal gives Fresenius Kabi
broader access to the U.S. transfusion technology market and
adds new momentum to building a global market presence in
this segment."
"The products, services, technologies and cultures of
both companies fit extremely well together," said Ron
Labrum, Fenwal president and chief executive officer.
"We are committed to assuring a smooth integration with
Fresenius Kabi and to bring our customers even more value as
a result of this unique combination."
The two companies' business activities perfectly
complement each other: Fenwal holds an excellent position in
the market for automated blood collection devices, while
Fresenius Kabi is a major supplier of blood bags and filters
used for manual blood collection. Combining the two
businesses will lead to the most comprehensive product
portfolio in transfusion medicine.
In addition, the acquisition will enhance Fresenius
Kabi's geographical presence. Fenwal, headquartered in
Lake Zurich, Illinois, generates more than half its sales in
the United States, where its infrastructure will serve as a
platform for further growth opportunities for Fresenius Kabi.
Vice versa, Fresenius Kabi's international network will
expand Fenwal's global product reach. Significant
potential for revenue and cost synergies will be created.
Around the world, approximately 92 million whole blood
donations are collected annually*. The transfusion technology
market is mainly driven by demographic developments and the
growing demand for products for automated blood component
processing. In addition, the increasing demand in emerging
markets will lead to further growth in this product
segment.
* www.who.int/worldblooddonorday/en/index.html
Financial terms were not disclosed. The transaction will be
financed initially from existing funds, whereas the
enterprise value does not exceed the proceeds of the May 2012
capital increase. Irrespective of acquiring Fenwal, Fresenius
continues to assess its options for an acquisition of
Rhön-Klinikum AG.
The transaction is subject to the necessary regulatory
approvals by the relevant antitrust authorities, and is
expected to close at the end of 2012.
Telephone Conference
A telephone conference will be held at 2.30 p.m.
CEST on Monday, July 23, 2012. You are cordially invited to
follow the conference call in a live broadcast via the
Internet at www.fresenius.com, Investor Relations,
Presentations. Following the call, a replay will be available
on our website.
Automated and manual blood collection
Automated technology allows blood to be
automatically separated into its therapeutic components,
collecting only what is needed from donors - red blood cells,
platelets, plasma, or therapeutic proteins. This enables
blood centers to optimize each donation, limits further
processing steps, and helps to ensure the right blood
components are available in hospitals to meet patient
needs.
During a manual blood collection the blood is collected from
a donor and manually processed in a laboratory into its
therapeutic components.
###
Fresenius is a health care group with international
operations, providing products and services for dialysis,
hospital and outpatient medical care. In 2011, Group sales
were €16.5 billion. As of March 31, 2012, the Fresenius Group
had 160,249 employees worldwide.
For more information visit the company's website at
www.fresenius.com
.
Fresenius Kabi is focused on the therapy and care of
critically and chronically ill patients inside and outside
the hospital. Its portfolio comprises a wide range of IV
drugs, infusion therapies, clinical nutrition products as
well as the related medical devices. With a corporate
philosophy of "caring for life," the company's
goal is to improve the patient's quality of life. In
2011, Fresenius Kabi's sales were €3,964 million and the
company's EBIT was €803 million. Fresenius Kabi has
24,632 employees worldwide (March 31, 2012).
Fresenius Kabi AG is a 100% subsidiary of the health care
group Fresenius SE & Co. KGaA.
This release contains forward-looking statements that are
subject to various risks and uncertainties. Future results
could differ materially from those described in these
forward-looking statements due to certain factors, e.g.
changes in business, economic and competitive conditions,
regulatory reforms, results of clinical trials, foreign
exchange rate fluctuations, uncertainties in litigation or
investigative proceedings, and the availability of financing.
Fresenius does not undertake any responsibility to update the
forward-looking statements in this release.
Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Dr. Ulf M. Schneider (Chairman), Rainer
Baule, Dr. Francesco De Meo,
Dr. Jürgen Götz, Dr. Ben Lipps, Stephan Sturm, Dr. Ernst
Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick
distributed by |